Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

Type of Cancer
Lymphoma

Sponsor
Pharmacyclics

Protocol Number
PCYC-1145-LT

To Learn More Call
(201)-510-0950